Adjuvant Aflibercept for Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate if aflibercept can reduce the chance that
metastatic (spread of) colorectal cancer can grow back after finishing standard treatment.
The study will also look at the side effects of aflibercept and the effect on quality of
life.
Phase:
Phase 2
Details
Lead Sponsor:
Brown University
Collaborators:
Lifespan Montefiore Medical Center Rhode Island Hospital Sanofi The Miriam Hospital University of California, San Diego University of Florida